Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.
- Resource Type
- Article
- Source
- Radiology & Oncology; Jun2022, Vol. 56 Issue 2, p238-247, 10p
- Subject
DISEASE progression LETROZOLE ONCOGENES NEUTROPENIA TREATMENT effectiveness AMINOTRANSFERASES HORMONE receptor positive breast cancer PATIENT safety - Language
- ISSN
- 13182099